NCT07830719ClinicalTrials.gov
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
En resumen
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and…
Fase 2180 participantes buscados23 centros5 países
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07830719Abrir este registro en ClinicalTrials.govSincronizado el mes pasado
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 3 days after the recorded start)First posted 2026-09-21; recorded start 2026-09-18
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study, international in scope: 180 participants (target), run at 23 sites, across 5 countries.
How this score is built
- Enrolment21/40
180 participants (target)
- Site count0/25
1 sites
- Country count0/15
Single country
- Planned duration5/10
Planned over about 13 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,133 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)
Afecciones
- Coronary Artery Disease
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – 80 Years |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 2 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | QUADRUPLE (4) |
| Inscripción | 180 participantes buscados |
Patrocinador y colaboradores
- Novartis Pharmaceuticals Patrocinador
Grupos e intervenciones
- YMI024 Dose 1EXPERIMENTAL
Participants receive YMI024 Dose 1 in addition to standard-of-care therapies.
- YMI024 Dose 2EXPERIMENTAL
Participants receive YMI024 Dose 2 in addition to standard-of-care therapies.
- YMI024 Dose 3EXPERIMENTAL
Participants receive YMI024 Dose 3 in addition to standard-of-care therapies.
- YMI024 Dose 4EXPERIMENTAL
Participants receive YMI024 Dose 4 in addition to standard-of-care therapies.
- YMI024 Dose 5EXPERIMENTAL
Participants receive YMI024 Dose 5 in addition to standard-of-care therapies.
- PlaceboPLACEBO_COMPARATOR
Participants receive a matching placebo in addition to standard-of-care therapies
Intervenciones
- Fármaco Placebo
matching placebo
- Fármaco YMI024
YMI024 in different doses
Variables de resultado
Variable de resultado principal
Change from baseline in log-transformed IL-6
Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology
Plazo Baseline and approximately 3 months
Variable de resultado secundaria
Change from baseline in log-transformed IL-6
Change from baseline in log-transformed IL-6 to characterize the dose-response relationship for YMI024 in IL-6 using the model-based (Mod) component of the MCP-Mod methodology
Plazo Baseline and approximately 3 months
Variable de resultado secundaria
Change from baseline in log-transformed hsCRP
Change from baseline in log-transformed high-sensitivity C-reactive protein (hsCRP)
Plazo Baseline and approximately 3 months
Variable de resultado secundaria
Responder status - hsCRP <2 mg/L
Responder status (Yes/No), defined as hsCRP \<2 mg/L
Plazo Approximately 3 months
Variable de resultado secundaria
Responder status - hsCRP <1 mg/L
Responder status (Yes/No), defined as hsCRP \<1 mg/L
Plazo Approximately 3 months
Variable de resultado secundaria
Number of participants with adverse events
Number of participants with adverse events, including abnormal vital signs, ECGs, and laboratory assessments
Plazo Approximately 4 months
Fechas
| Fecha de inicio | 18 de septiembre de 2026 (real) |
|---|---|
| Finalización principal | 15 de agosto de 2027 (estimada) |
| Finalización | 15 de agosto de 2027 (estimada) |
| Primera publicación | 21 de septiembre de 2026 (real) |
| Última actualización | 15 de octubre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | octubre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
23 centros están en reclutamiento
Australia
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Novartis Investigative Site | Adelaide | South Australia | En reclutamiento |
| Novartis Investigative Site | Frankston | Victoria | En reclutamiento |
| Novartis Investigative Site | Melbourne | Victoria | En reclutamiento |
| Novartis Investigative Site | Mulgrave | Victoria | En reclutamiento |
Germany
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Novartis Investigative Site | Berlin | En reclutamiento | |
| Novartis Investigative Site | Kaiserslautern | Rhineland-Palatinate | En reclutamiento |
| Novartis Investigative Site | Mannheim | En reclutamiento | |
| Novartis Investigative Site | Pirna | En reclutamiento | |
| Novartis Investigative Site | Stuttgart | Baden-Wurttemberg | En reclutamiento |
Japan
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Novartis Investigative Site | Kamakura | Kanagawa | En reclutamiento |
| Novartis Investigative Site | Kasugai | Aichi-ken | En reclutamiento |
| Novartis Investigative Site | Matsubara | Osaka | En reclutamiento |
| Novartis Investigative Site | Matsudo | Chiba | En reclutamiento |
United Kingdom
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Novartis Investigative Site | London | En reclutamiento |
United States
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Pharma Tex Research | Amarillo | Texas | En reclutamiento |
| AMR Miami | Coral Gables | Florida | En reclutamiento |
| Eastern Shore Research Institute | Fairhope | Alabama | En reclutamiento |
| G and L Research LLC | Foley | Alabama | En reclutamiento |
| Anderson Medical Research | Ft. Washington | Maryland | En reclutamiento |
| Biopharma Informatic LLC | Los Angeles | California | En reclutamiento |
| MD Medical Research | Oxon Hill | Maryland | En reclutamiento |
| Alliance for Multispecialty Research | Wichita | Kansas | En reclutamiento |
| Selma Medical Associates | Winchester | Virginia | En reclutamiento |
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 15 de octubre de 2026
Fecha de finalización adelantada
Primary completion advanced 65 days
2027-10-192027-08-15
- 15 de octubre de 2026
Centro añadido
22 sites added (23 total)
123
- 24 de septiembre de 2026
Estado modificado
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24 de septiembre de 2026
Reclutamiento abierto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24 de septiembre de 2026
Fecha de finalización aplazada
Primary completion delayed 33 days
2027-09-162027-10-19
- 24 de septiembre de 2026
Centro añadido
1 site added (1 total)
01